RNS Number : 4777G
Verona Pharma PLC
30 May 2017
 

 

 
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

 

 

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ii

Verona Pharma plc   

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

3. Full name of person(s) subject to the
notification obligation: iii

Vivo Ventures VII, LLC

4. Full name of shareholder(s)
 (if different from 3.):iv

Vivo Ventures fund VII, LP

Vivo Ventures VII Affiliates Fund, LP

5. Date of the transaction and date on
which the threshold is crossed or
reached: v

April 28, 2017

6. Date on which issuer notified:

April 28, 2017

7. Threshold(s) that is/are crossed or
reached: vi, vii

9.84% to 9.14% Change at Combined Interest Level
           
 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary

GB00B06GSH43

5,047,877

5,047,877

5,047,877

 

5,047,877

 

4.83%

 

ADS

US925050106

 

0

0

4,507,040

 

 

4,507,040

 

4.31%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date xiii

Exercise/
Conversion Period xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

9,554,917

9.14%
                                 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi

Vivo Ventures VII, LLC is the general partner of both Vivo Ventures Fund VII, LP (VV Fund VII)

and Vivo Ventures VII Affiliates Fund, LP. (Affiliates Fund VII). Accordingly, Vivo Ventures VII,

LLC may be deemed to have indirect beneficial ownership of shares of the Issuer directly owned

by VV Fund VII and Affiliates Fund VII. As of the date of this filing, VV Fund VII and Affiliates

Fund VII beneficially own 9,351,110 and 203,807 shares of Common Stock respectively.

 

 

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease
to hold:

 

12. Date on which proxy holder will cease to hold
voting rights:

 

 


13. Additional information:


 

14. Contact name:

Vivo Capital, LLC

Attn: Cinthia Sheu

15. Contact telephone number:

+1-650-688-0818
     
 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPGUUWAUPMPUB